Sanofi Submits IND Application in China for First-in-Class Bispecific Nanobody SAR442970 Targeting TNFα and OX40L
Sanofi
Pharmaceutical R&D Developer
▎WuXi AppTec Content Team Report
Today (October 24), the official website of the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) announced,Sanofi (Sanofi)The clinical trial application for SAR442970 Injection, a Class 1 new drug developed by Sanofi, has been accepted.Public information shows that SAR442970 is aBispecific Nanobody (VHH) Targeting TNFα and OX40L, which is currently in Phase 2 clinical trials internationally.This is the first time that the product has been submitted for an IND application in China.
Screenshot source:CDE Official Website
SAR442970 Injection is a bispecific antibody developed based on Nanobody technology.According to the previously disclosed information from Sanofi,Through connectionNanobody MoleculeFragments, the company's team can create new compounds (called "multivalent" nanobody molecules) that can bind to multiple different targets at once. For example,A single therapeutic nanobody molecule can establish a bridge between tumor cells and immune cells by binding to multiple sites on both, helping the body's immune system fight cancer.。
According to the pipeline information on Sanofi's official website, the company has several bispecific nanobodies based on Nanobody technology under development.SAR442970 injection is one of them.，This product targets TNFα and OX40L.。
The application potential of TNFα and OX40L in inflammation and autoimmune diseases has been clinically validated in a series of trials. Sanofi has previously developed programs targeting both of these, having already researched and developedMonoclonal Antibody Targeting OX40LamlitelimabSanofi believes that the drug has the potential to become a blockbuster; as well as developed an oral TNFα inhibitor referred to as the "next-generation oral medication."SAR441566。
According toClinicalTrialsOfficial website, currently, Sanofi is conducting two Phase 2 clinical trials internationally for SAR442970 injection, one of which is to evaluate SAR442970 compared with placebo in the treatment ofAdult Suppurative HidradenitisEfficacy and safety. In this study,The patient will receive an injection of SAR442970 every two weeks (Q2W).Another study will evaluate the efficacy and safety of SAR442970 compared with two other positive control drugs in treating patients with primary focal segmental glomerulosclerosis or minimal change disease.
This timeSAR442970 Injection Submitted for Clinical Trial in China, Indicating the Product is Expected to Commence Clinical Research in China Soon.
[1] Center for Drug Evaluation, National Medical Products Administration of ChinaWebsite. Retrieved Oct 24, 2024, from https://www.cde.org.cn/main/xxgk/listpage/da6efd086c099b7fc949121166f0130c
[2] Sanofi Official Website. From https://www.sanofi.com/en/our-science/our-pipeline
ThisText from the WuXi AppTec content team. Individuals are welcome to share it on their social media feeds, but unauthorized republication in any form by media or organizations to other platforms is strictly prohibited.Reprint Authorization andFor other collaboration needs, please contact wuxi_media@wuxiapptec.com.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it indicate that WuXi AppTec supports or opposes the views mentioned. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.
